Literature DB >> 11318526

Increased levels of gammaGT suggest the presence of bile duct lesions in patients with chronic hepatitis C: absence of influence of HCV genotype, HCV-RNA serum levels, and HGV infection on this histological damage.

E Giannini1, F Botta, A Fasoli, P Romagnoli, L Mastracci, P Ceppa, I Comino, A Pasini, D Risso, R Testa.   

Abstract

Damage to bile ducts in chronic hepatitis C is a characteristic histological lesion. Moreover, the presence of abnormal levels of gammaGT in these patients is also a common finding. Assessing whether the presence of bile duct lesions is indicated by biochemical abnormalities or whether virological characteristics can influence their development may help in the definition of clinical-histological relationships in chronic hepatitis C. In this study we evaluated the relationships among routine biochemical parameters, serum bile acids, and pi-class glutathione S-transferase levels, and the presence of bile duct lesions in 60 patients with chronic hepatitis C. Furthermore, we assessed whether the presence of bile duct lesion might be related to HCV genotype, HCV-RNA serum levels, and positivity for HGV-RNA. We found that gammaGT was the only parameter related to the presence of bile duct lesions. Although a trend towards higher serum bile acids and pi-class glutathione S-transferase levels was observed in patients with bile duct lesions, this trend did not reach statistical significance. Different HCV genotypes and RNA levels, and HGV-RNA positivity did not seem to influence the presence of bile duct damage. In conclusion we found that gammaGT levels point out the presence of bile duct lesions in patients with chronic hepatitis C. Since we observed a different pattern of alteration of gammaGT, serum bile acids, and pi-class glutathione S-transferase, we suggest that these various biochemical alterations reflect a more complex damage to bile duct structures, which is not likely represented by the common assessment of bile duct lesions. Viral factors such as HCV genotype and RNA levels as well as HGV-RNA positivity are probably not the main cause of this histological damage.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11318526     DOI: 10.1023/a:1005534929304

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  31 in total

1.  Assessment of activity in chronic active liver disease. Serum bile acids compared with conventional tests and histology.

Authors:  M G Korman; A F Hofmann; W H Summerskill
Journal:  N Engl J Med       Date:  1974-06-20       Impact factor: 91.245

2.  Pruritus in chronic hepatitis C: association with high serum bile acids, advanced pathology, and bile duct abnormalities.

Authors:  E Lebovics; F Seif; D Kim; A Elhosseiny; B M Dworkin; A Casellas; S Clark; W S Rosenthal
Journal:  Dig Dis Sci       Date:  1997-05       Impact factor: 3.199

3.  The utility of noninvasive serologic markers in the management of early allograft rejection in liver transplantation recipients.

Authors:  R C Dickson; G Y Lauwers; C B Rosen; R Cantwell; D R Nelson; J Y Lau
Journal:  Transplantation       Date:  1999-07-27       Impact factor: 4.939

4.  Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C.

Authors:  P H McGuinness; G A Bishop; D M Painter; R Chan; G W McCaughan
Journal:  Hepatology       Date:  1996-04       Impact factor: 17.425

5.  Hepatitis G virus RNA in the serum of patients with elevated gamma glutamyl transpeptidase and alkaline phosphatase: a specific liver disease? [corrected].

Authors:  P Colombatto; A Randone; G Civitico; J Monti Gorin; L Dolci; N Medaina; F Oliveri; G Verme; G Marchiaro; R Pagni; P Karayiannis; H C Thomas; G Hess; F Bonino; M R Brunetto
Journal:  J Viral Hepat       Date:  1996-11       Impact factor: 3.728

6.  gamma-Glutamyl transpeptidase as a response predictor when using alpha-interferon to treat hepatitis C.

Authors:  D H Van Thiel; L Friedlander; P Malloy; H I Wright; A Gurakar; S Fagiuoli; W Irish
Journal:  Hepatogastroenterology       Date:  1995 Nov-Dec

Review 7.  Immune responses in hepatitis C virus infection.

Authors:  U Spengler; M Lechmann; B Irrgang; F L Dumoulin; T Sauerbruch
Journal:  J Hepatol       Date:  1996       Impact factor: 25.083

Review 8.  Histopathologic findings in chronic hepatitis C.

Authors:  H P Fischer; E Willsch; E Bierhoff; U Pfeifer
Journal:  J Hepatol       Date:  1996       Impact factor: 25.083

9.  Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group.

Authors:  J H Lefkowitch; E R Schiff; G L Davis; R P Perrillo; K Lindsay; H C Bodenheimer; L A Balart; T J Ortego; J Payne; J L Dienstag
Journal:  Gastroenterology       Date:  1993-02       Impact factor: 22.682

10.  Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: gamma GT levels predictive for response.

Authors:  G Mazzella; A Salzetta; S Casanova; M C Morelli; N Villanova; R Miniero; S Sottili; V Novelli; A Cipolla; D Festi
Journal:  Dig Dis Sci       Date:  1994-04       Impact factor: 3.199

View more
  10 in total

Review 1.  Liver enzyme alteration: a guide for clinicians.

Authors:  Edoardo G Giannini; Roberto Testa; Vincenzo Savarino
Journal:  CMAJ       Date:  2005-02-01       Impact factor: 8.262

2.  A review on laboratory liver function tests.

Authors:  Shivaraj Gowda; Prakash B Desai; Vinayak V Hull; Avinash A K Math; Sonal N Vernekar; Shruthi S Kulkarni
Journal:  Pan Afr Med J       Date:  2009-11-22

3.  The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection.

Authors:  Viola Weich; Eva Herrmann; Tje Lin Chung; Christoph Sarrazin; Holger Hinrichsen; Peter Buggisch; Tilman Gerlach; Hartwig Klinker; Ulrich Spengler; Alexandra Bergk; Stefan Zeuzem; Thomas Berg
Journal:  J Gastroenterol       Date:  2011-09-13       Impact factor: 7.527

4.  Association of serum gamma-glutamyl transferase with treatment outcome in chronic hepatitis B patients.

Authors:  Rui Huang; Chen-Chen Yang; Yong Liu; Juan Xia; Ran Su; Ya-Li Xiong; Gui-Yang Wang; Zhen-Hua Sun; Xiao-Min Yan; Shan Lu; Chao Wu
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

5.  Glutathione-S-transferase subtypes α and π as a tool to predict and monitor graft failure or regeneration in a pilot study of living donor liver transplantation.

Authors:  C Jochum; M Beste; J-P Sowa; M S Farahani; V Penndorf; S Nadalin; F Saner; A Canbay; Guido Gerken
Journal:  Eur J Med Res       Date:  2011-01-27       Impact factor: 2.175

Review 6.  Hepatitis C virus-associated pruritus: Etiopathogenesis and therapeutic strategies.

Authors:  Youssef Alhmada; Denis Selimovic; Fadi Murad; Sarah-Lilly Hassan; Youssef Haikel; Mossaad Megahed; Matthias Hannig; Mohamed Hassan
Journal:  World J Gastroenterol       Date:  2017-02-07       Impact factor: 5.742

7.  Influence of resveratrol on liver fibrosis induced by dimethylnitrosamine in male rats.

Authors:  Suzan B Abdu; Fatima M Al-Bogami
Journal:  Saudi J Biol Sci       Date:  2017-09-21       Impact factor: 4.219

8.  A lower serum gamma-glutamyltransferase level does not predict a sustained virological response in patients with chronic hepatitis C genotype 1.

Authors:  Fatih Güzelbulut; Mesut Sezikli; Züleyha Akkan Cetinkaya; Selvinaz Ozkara; Can Gönen; Ayşe Oya Kurdaş Ovünç
Journal:  Gut Liver       Date:  2012-11-13       Impact factor: 4.519

9.  Prognostic Significance of Elevated Cholestatic Enzymes for Fibrosis and Hepatocellular Carcinoma in Hospital Discharged Chronic Viral Hepatitis Patients.

Authors:  Wen Xie; Yang Cao; Min Xu; Jiangbin Wang; Changyu Zhou; Xingxiang Yang; Xiaoxia Geng; Wenhong Zhang; Ning Li; Jun Cheng
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

10.  Liver Enzymes in Early to Mid-pregnancy, Insulin Resistance, and Gestational Diabetes Risk: A Longitudinal Analysis.

Authors:  Yeyi Zhu; Monique M Hedderson; Charles P Quesenberry; Juanran Feng; Assiamira Ferrara
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-02       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.